Credit Suisse’s Mural Oncology MURA Stock Holding History

Credit Suisse’s Portfolio MURA Stock Details MURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-22,758	Closed	-$135K	–	3006
2023 Q4	$135K	Buy	+22,758	New	+$91.5K	﹤0.01%	3014

Other funds holding MURA

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

AFA

Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's MURA Position: Q1 2024 in Review

Credit Suisse sold out of Mural Oncology (MURA) in Q1 2024, closing a stake of 22,758 shares — an estimated $135K sold.

Credit Suisse first reported a position in MURA in Q4 2023 and held it in 1 quarter. The position peaked at $135K in Q4 2023. 101 funds tracked by Wall St. Rank hold MURA as of Q1 2024.

Credit Suisse reported no remaining Mural Oncology position as of Q1 2024 after selling out during the quarter.
Credit Suisse sold 22,758 Mural Oncology shares in Q1 2024, an estimated $135K.
Credit Suisse first reported a position in Mural Oncology in Q4 2023 and held it in 1 quarter.
Credit Suisse's Mural Oncology position peaked at $135K in Q4 2023.
101 funds tracked by Wall St. Rank held Mural Oncology as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.